SWOG-9704 A Randomized Phase III Trial Comparing Early High Dose Chemoradiotherapy and an Autologous Stem Cell Transplant to Conventional Dose CHOP Chemotherapy Plus Rituximab for CD20+ B Cell Lymphomas (With Possible Late Autologous Stem Cell Transplant) for Patients With Diffuse Aggressive Non-Hodgkin's Lymphoma in the High-Intermediate and High Risk International Classification Prognostic Groups
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Carmustine; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 02 Feb 2021 Biomarkers information updated
- 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
- 14 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by National Cancer Institute of Canada record.